News for ORIC Pharmaceuticals, Inc. (ORIC)

On June 9, 2025, Dominic Piscitelli, the Chief Financial Officer of ORIC Pharmaceuticals Inc, executed a sale of 2,900 shares of the company. Following this tra

ORIC Pharmaceuticals (ORIC) has granted 39,100 non-qualified stock options and 6,500 restricted stock units to three new employees. These grants were approv

**media[648056]**

U.S. stocks traded mostly higher midway through trading, with the S&P 500 gaining around 0.4% on Thursday. The Dow traded up 0.03% to 42,113.07 while the NASDA...

U.S. stocks were mostly higher, with the Nasdaq Composite gaining around 100 points on Thursday. Shares of Veeva Systems Inc. VEEV rose sharply during Thursday...

JPMorgan has expressed significant optimism regarding Oric Pharmaceuticals (ORIC) following the Phase 1b dose-escalation trial results for ORIC-944, which is co

Florida-based Zeo Energy Corp. (ZEO) is up over 121 percent in Thursday's pre-market trading. The following are some of the other stocks making big moves in Thursday's pre-market trading.

Shares of NVIDIA Corporation NVDA rose sharply in today's pre-market trading after the company posted first-quarter results. The company reported first-quarter...

ORIC Pharmaceuticals, Inc.

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) has unveiled promising early results from its Phase 1b trial of ORIC-944, a novel PRC2 inhibitor, in combination with androgen receptor inhibitors for metastatic castration-resistant prostate cancer (mCRPC). The study reported broad and deep prostate-specific antigen (PSA) responses, with a 59% PSA50 response rate (47% confirmed, plus one pending) and a […]

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. ( ORIC), a clinical stage oncology company focused on d

Conference Call and Webcast on Wednesday, May 28, 2025, at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- ORIC Pha

**media[637950]**

We recently published a list of the 13 Best Biotech Penny Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where ORIC Pharmaceuticals Inc. (NASDAQ:ORIC) stands against other biotech penny stocks. Peter Marks’s departure from the FDA has left innovators concerned regarding the current state of […]

**media[587774]**

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 04, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (ORIC), a clinical stage oncology company focused on

**media[586416]**

**media[582041]**

**media[576532]**